Reuters reports that Pfizer has partially won a patent case against Indian company Ranbaxy in the Netherlands. The win concerns the basic patent over atorvastatin, the active ingredient in Lipitor, and will prevent Ranbaxy from launching a generic version of Lipitor until the atorvastatin patent expires in 2011. Pfizer also lost an invalidity claim concerning the patent salt of atorvastatin.
The IPKat invites his readers to compare the case to the other Lipitor decisions.
LIPITOR WIN IN NETHERLANDS
![LIPITOR WIN IN NETHERLANDS]()
Reviewed by Anonymous
on
Wednesday, September 13, 2006
Rating:
Follow the IPKat on LinkedIn 
![[Guest post] Asking ourselves ‘Y’ – Are shape marks shaping complex products’ aftermarkets?](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhHwE0es_m0lzJpedp0KFtKOYBne_M3YPJ-qwQxiY_YMkHffLAAXkSW9F-pjQFKsy5kJJ-VWScQQkuEVb5-BxnDv10XIMAbYhvgzBSQadD1gdTiIjg9-Oj9Iekll-C3Ca9I76uI3Hh5nCI4QyLosLSNev9VzLq9lF1jM86ungheEDOBKLzGTbE3yw/s72-c/Picture%201.png)
![[Guest post] Flat rates supported by clauses on universality of repertoire in contracts between CMOs and users are anti-competitive, says Spanish Competition Authority](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhpBg7o3d7DPzH4YqNz3DUV5J5_sS4P7X7ZznFNETyQlLe0gonaSi3eE_jdjHD_aIjbPKhgpvUrkg6tPprYQYdwDGiyuWIXty9BOUlc07wUVbjDxI1bHoVxZA0ZCC9HBPjLXQwUioBSd9e9n-Z3uCeJ9UUgEvtJHLo1AllR20HGJETFdKoovxLBMw/s72-c/images.png)
![[Guest post] Thou shalt not discriminate the Lego block over any other kind of product – GRUR speaks out on C-211/24](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgWJYQUJNvYydrZcjwSHPuxd14xX3_48aBusHKBogY-Wg1BPSJSABbFFjmGiUV3aqG2npP9xYaIl1vtWK5AsqGOQPgRD2TWFLhyyc4xGm1fHDD-tt9kHcrSSgAyju2P9wSKz0VW6h7D5MD4Hxd9vREyxKYzlMRNXxxtxc3DiNsXppfVaxgSxAMV/s72-c/21742619125_7c9e53cd39_o.png)
Posts
No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html